Biogen Idec, Genentech, Genmab, GlaxoSmithKline, Roche cancer news

The U.S. Court of Appeals for the Federal Circuit upheld a 2011 lower court ruling in favor of GlaxoSmithKline and Genmab related to the companies' cancer drug Arzerra ofatumumab. In 2010, Biogen Idec and Roche's Genentech unit filed the suit in the U.S. District Court for the Southern District of California alleging that Arzerra infringes U.S. Patent No. 7,682,612, covering methods of treating chronic lymphocytic leukemia (CLL) with anti- CD20 antibodies. GSK, which has worldwide co-development and commercialization rights, markets the human mAb against CD20 in the U.S. and EU to treat CLL refractory to fludarabine and alemtuzumab (see BioCentury, March 29, 2010). ...